This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Good morning. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Comerica Second Quarter 2018 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions].
CMA.WS DB MS.PRI CMA MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA CMPWW
Have you been eager to see how Comerica Incorporated (CMA - Free Report) performed in Q2 in comparison with the market expectations? Let’s quickly scan through the key facts from this Texas-based money center bank’s earnings release this morning:
CDMO CMA.WS CMA SGH CMPWW
M&T Bank Corporation (MTB - Free Report) is scheduled to report second-quarter 2018 results on Jul 18, before the opening bell. The company’s revenues and earnings are expected to improve from the year-ago quarter.
CMA.WS POOL CMA GTT CFR CMPWW
Morgan Stanley’s (MS - Free Report) second-quarter 2018 results, slated on Wednesday, Jul 18, are likely to get support from normalized trading levels. Thus, trading income, one of the major revenue components, is expected to have a positive impact on the company’s earnings. Unlike the first quarter when higher inflation expectation, tightening of monetary policy by the Fed, impending U.S.-China trade war and a sharp sell-off in the tech sector incited volatility, developments like further escalation in the trade war and some other geo-political tensions in the second quarter were not enough to lead to substantial rise in client activity.
STI.WS.B CMA.WS POOL STI.WS.A CMA MS.PRE MS.PRF MS.PRG MS.PRA KEY CMPWW STI MS.PRI GTT MS.PRK STI-A STI.PRE MS
Ericsson (ERIC - Free Report) is scheduled to report second-quarter 2018 results before the opening bell on Jul 18. The company has a bleak earnings history with consecutive colossal earnings misses. However, Ericsson managed to beat estimates by 4 cents in the last reported quarter with an average negative surprise of 269.2% in the trailing four quarters. Let's see how things are shaping up for this announcement and whether Ericsson can beat earnings this quarter.
CMA.WS POOL CMA GTT VZ NVDA CMPWW VZA
Higher-than-expected trading revenues and rise in demand for loans drove JPMorgan’s (JPM - Free Report) second-quarter 2018 earnings of $2.29 per share, which outpaced the Zacks Consensus Estimate of $2.22. The figure was up 26% from the prior-year quarter. The stock rose nearly 1% in the pre-market trading, indicating that investors have taken the results in their stride. Notably, the full-day trading session will depict a better picture.
BAC USB BAC CMA.WS CMA CMPWW
The Charles Schwab Corporation (SCHW - Free Report) is scheduled to report second-quarter 2018 results on Jul 17, before the market opens. Its revenues and earnings are projected to grow year over year. In the last reported quarter, the company’s earnings surpassed the Zacks Consensus Estimate. Revenue growth, significant rise in total client assets and new brokerage accounts were among the positives.
SCHW.PRBCL CMA.WS CMA KEY SAM CMPWW
BlackRock, Inc. (BLK - Free Report) is slated to report second-quarter 2018 results on Jul 16, before the opening bell. Its revenues and earnings are projected to grow year over year. In the last reported quarter, the company’s earnings surpassed the Zacks Consensus Estimate. Results benefited from an improvement in revenues, rise in assets under management (AUM) and long-term inflows. Moreover, the company boasts a decent earnings surprise history.
BLK CMA.WS CMA KEY SAM CMPWW
Comerica Incorporated (CMA - Free Report) is scheduled to report second-quarter 2018 results before the opening bell on Jul 17. Its revenues and earnings are expected to grow year over year.
STT CMA.WS STT.PRC CMA STT.PRE STT.PRD BKU STT.PRG KEY SAM CMPWW
In the last five trading days, bank stocks delivered a bullish performance. While escalating trade war between the United States, China and the European Union continued to weigh on investor sentiments, strong economic data on the domestic front largely mitigated this. The latest job market data lessened the concern that the economy is in the late stage of expansion. This news resulted in rising yield on benchmark 10-year Treasury Notes.
WFCNP COF.PRG COF.PRH CMA.WS COF.WS WFC.PRL COF.PRP WFC.PRJ KEY FITBI SAM CMPWW BAC USB COF-D WFC.PRT COF-C COF-F WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY COF.PRC WFC.PRX COF.PRD WFC.PRW WFC.PRV COF.PRF BBT WFC WFC.WS BAC C COF-P CMA COF OZRK BLK FITB
ADTRAN, Inc. (ADTN - Free Report) is scheduled to report second-quarter 2018 results after the closing bell on Jul 17. Although this communication infrastructure provider delivered an average positive surprise of 51.3% in the trailing four quarters, it widely missed earnings estimates in the last quarter. Let's see how things are shaping up for this announcement. Factors to Consider ADTRAN is accelerating the industry’s transition to open, programmable, scalable networks by leveraging its Mosaic Software-Defined Access architecture that combines modern Web-scale technologies with open-source platforms to facilitate rapid innovation in multi-technology, multi-vendor environments.
CMA.WS CMA WDAY ADTN NVDA SAM CMPWW
The PNC Financial Services Group (PNC - Free Report) is scheduled to report second-quarter 2018 results on Jul 13, before the opening bell. Its revenues and earnings are projected to grow year over year. In the last reported quarter, the company’s earnings surpassed the Zacks Consensus Estimate. Results benefited from an improvement in net interest income as well as non-interest income, partially offset by higher expenses.
LMT CMA.WS CMA PNC.PRP PNC.PRQ PNCFO CMPWW PNC.WS 7018 CME ETFC PNC PNUCL
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET